Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

Efficacy of Glycaemic Control of Biphasic Insulin Aspart (NovoMix® 30) or Insulin Detemir (Levemir®) in Patients With Type 1 or 2 Diabetes Mellitus

This trial is conducted in Europe.

The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.

Inclusion Criteria:

• Patients with Type 1 or Type 2 diabetes, including newly diagnosed
• Age: Levemir® above 6 years
• Age: Novomix® above 18 years

Exclusion Criteria:

• Current treatment with NovoMix® 30 or Levemir®